Home Journals Articles Updates About
CN
image
收藏切换
N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis
收藏切换
PDF
Dake Liua, Shuyan Liub, Fanlei Hub, *, Zhongtang Lia, *, Zhongjun Lia, *
Chinese Chemical Letters | 2024, 35(5) : 108762
Less
收藏切换
Chinese Chemical Letters | 2024, 35(5): 108762
• Communication •
N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis
Full
Dake Liua, Shuyan Liub, Fanlei Hub, *, Zhongtang Lia, *, Zhongjun Lia, *
Affiliations
  • a State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
  • b Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
Published: 2024-05-15 doi: 10.1016/j.cclet.2023.108762
Outline
收藏切换

The interaction among type Ⅱ collagen (CII), human DR4 major histocompatibility complex type Ⅱ molecule (MHC Ⅱ) and T-cell receptor (TCR) is associated with the development of rheumatoid arthritis (RA). The activation of T cells can be reduced through exposure to modified CII(263–272) glycopeptide fragment via competitive inhibition with self-antigen. In this work, 30 peptides based on the sequence of CII(263–272) were prepared and evaluated for their binding to DR4 protein by surface plasmon resonance (SPR) assay. The effect on the secretion of pro-inflammatory factors by the spleen cells in collagen induced rheumatoid arthritis (CIA) mouse was also investigated. Two N-glycosylated CII peptides were identified to have strong binding to the human recombinant DR4 protein and weak proinflammatory effect. These glycopeptides could be developed as therapeutic saccharide vaccines for the treatment of rheumatoid arthritis (RA).

Rheumatoid arthritis  /  Type Ⅱ collegan  /  Glycosylation  /  N-Glycosylated altered peptides  /  Saccharide vaccines
Dake Liu, Shuyan Liu, Fanlei Hu, Zhongtang Li, Zhongjun Li. N-Glycosylated type Ⅱ collagen peptides as therapeutic saccharide vaccines for rheumatoid arthritis[J]. Chinese Chemical Letters, 2024 , 35 (5) : 108762 - . DOI: 10.1016/j.cclet.2023.108762
Full Text
Less
Rheumatoid arthritis (RA) is a systemic autoimmune disease with an incidence of 0.5%–1.0% in the world, affecting peripheral joints by causing chronic inflammation that destroys cartilage and bone [1,2]. The etiology of RA is not fully understood, which greatly limits the development of clinical therapy. Type Ⅱ collagen which is the major component in the cartilage matrix has been suggested to be an autoantigen associated with collagen-induced arthritis (CIA) [3]. The occurrence of CIA is related to the specific recognition of CII bound major histocompatibility complex class Ⅱ (MHC Ⅱ) molecules that are present on an antigen-presenting cell by T-cell receptors (TCR) [4]. The TCR/antigen/MHC Ⅱ complex is essential for the immune system to distinguish the body's own constituents and foreign antigens [5].
The CII(263–272) fragment (Fig. 1A) is the immunodominant epitope of CII and the main antigen that binds to human leukocyte antigen DR (HLA-DR) molecule via hydrogen bonding [6]. Ile260 and Phe263 are anchored to the HLA-DR binding groove, constituting the main sites for HLA-DR molecular binding [6]. Glu266, Lys270 and glycosylated Lys264 are the crucial sites for the recognition by TCR [7]. The carbohydrate moiety at Lys264 in natural CII greatly affects the incidence and severity of CIA [8]. There are two types of glycosylation modification in natural CII (Fig. 1B): galactose Gal(β1-O) or disaccharide Glc(α1–2)-Gal(β1-O) [9]. CII has important biological functions since 5–hydroxy-lysine can undergo such glycosylation modification.
Previous studies have shown that the structurally modified CII glycopeptide can significantly affect the activation of T cells by competitive inhibition with self-antigen, thereby inhibiting CIA. Those structural modifications have mainly focused on the substitution of amino acids on the CII immune dominant epitope [10–13] and the change of the hydroxyl of carbohydrate moiety sites [14,15]. The difficulty to synthesize 5-hydroxylysine glycosylated derivatives has greatly limited the study of structure-activity relationship of modified peptides. Glutamine (Gln) has a similar long side chain as that of 5-hydroxylysine. The more soluble and stable N-glycosylation derivatives at Gln-can be used to replace the O-glycosylated 5-hydroxylysine for specific recognition of CII peptide and TCR [16]. The synthesis of N-glycopeptides can be easily proceeded by using N-glycosylated Gln since N-glycosidic bond construction is more efficient. Moreover, the challenge to prepare chiral 5-hydroxylysine could be avoided [17–19]. Furthermore, large and complex carbohydrate moiety may eliminate the specific recognition of the CII glycopeptide with TCR [20]. In addition, it was shown that replacing Ile260 and Phe263 with Ala or Gly in CII results in markedly reduced affinities for the DR4 protein [21]. Similarly, recognition of the CII glycopeptide by TCR could be reduced with the substitutions of Ala or Gly for Gln267 and Lys270.
In this study, we designed and synthesized a new type of N-glycosylated Gln-modified CII peptides based on the sequence from CII(263–272), and explored their binding to DR4 protein as well as the recognition by TCR. N-Linked CII glycopeptides were synthesized from N-glycosylglutamic acid and non-glycosylated natural amino acids. Phe263 was retained in the designed peptides since it is crucial for binding to the MHC Ⅱ molecule. Some amino acids in CII(263–272) were replaced with Ala or Gly with short side chains for the purpose of reducing T-cell recognition. All peptides were evaluated for their binding to DR4 protein and stimulation of spleen cells from CIA mice in vitro to investigate their potential to be used for the treatment of RA.
Lysine derivative 1-13 was synthesized from protected aspartic acid 1-1 in 4% yield as shown in Scheme S1 (Supporting information) [22], which was used for the synthesis of O-galactose lysine 3a. To characterize the chiral purity of compound 1-13, we tested the specific rotation of compound 1-9, [α]D20 = −20.7 (c = 1.000, CHCl3), [α]D20 = −19.8 as a reference value [22]. The synthesis of galactopyranosyl trichloroacetimidate 2a [23] and aminoglycosides 2b–2d are shown in Supporting information (Experimental Section) [24], which were used for the synthesis of glycosylated amino acids 3a–3d.
Galactosyl hydroxylysine 3a was synthesized by the glycosylation of 2a and 1-13 catalyzed by trimethylsilyl trifluoromethanesulfonate (TMSOTf), followed by the removal of tert–butyl with trifluoroacetic acid (TFA) (Scheme 1A) [25]. Glycosyl glutamates 3b–3d were synthesized from aminoglycosides 2b–2d with Fmoc-protected glutamic acid in the presence of 2-(1H-benzotriazol-1-yl)−1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N,N-diisopropylethylamine (DIEA)/N,N-dimethylformamide (DMF), followed by the removal of tert–butyl with TFA (Scheme 1B) [26]. They were used to synthesize a series of N-linked CII peptides.
Thirty peptides based on sequence CII(263–272) were synthesized manually by Fmoc-based solid-phase synthesis (SPSS) using commercial Fmoc-protected amino acids and glycosylated amino acids 3a–3d (Table 1). Cleavage from the solid support with TFA/H2O/triisopropylsilane (TIS), followed by deacylation of the carbohydrate moieties by treatment with 5% hydrazine hydrate in DMF and purification by reversed-phase high performance liquid chromatography (HPLC) gave the designed peptides in 3%–35% yields. Native peptide fragment CII(263–272) and non-glycopeptides AP1–AP8 were obtained in 20%–35% yields. O-Galactopeptide 4a derived from galactosyl hydroxy–lysine 3a were obtained in 7% yield. N-Linked glycopeptides were obtained in 3%–13% yields. The purities of all peptides were more than 95% by reversed-phase HPLC analysis and their structures were confirmed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
The ability of the peptides to bind to human recombinant DR4 was determined by SPR assay. We found that 11 out of the 30 peptides were capable of binding to DR4 protein (Table 1). The binding ability of 4b-1, 4b-3 and 4b-4 to DR4 was stronger than 4a, while the binding ability of 4b-2, 4b-5, 4b-10 and 4b-12 to DR4 was weaker than 4a. These results suggested that the designed N-glycosylated CII peptides could bind to DR4 protein more strongly than the O-glycosylated CII peptide, and our subsequent research work should focus on the modification of galactosylated CII peptide rather than other glycoforms.
A model of the CII(263–272) in complex with a DR4 crystal structure was constructed from a reported structure (PDB ID: 1J8H). The designed glycopeptides 4a and 4b-1 were selected to be docked into the model to explore the comparative effects of the introduced glycosylated Lys264 moieties on the protein-ligand interactions (Fig. S1 in Supporting information). Assuming a similar binding mode as for the CII(263–272), the glycosylated Lys264 moieties in 4a and 4b-1, respectively, would be positioned on the border of the DR4 binding site. The backbones of the glycopeptides were similarly found fitting into the peptide-binding groove. The same conformations were also observed for the Gal O-glycosylated Lys264 (Gal-O-K, 4a) and Gal N-glycosylated Gln264 (Gal-N-E, 4b-1), which was consistent with the same binding affinities (KD = 4.84 µmol/mL for 4a and KD = 2.82 µmol/mL for 4b-1). But the replacement by Gal-N-E might affect the binding to TCR. Next, immunological assays were performed to evaluate the stimulation to TCR.
The effect of 4b-1 on the viability of spleen cells from CIA mice was detected by cell counting kit-8 (CCK-8) (Fig. S2 in Supporting information). Animal welfare and experiment process were reviewed and approved by Animal Ethics Committee of Peking University People's Hospital. The relative cell viability of each concentration group was slightly enhanced after 1.5 h treatment with compound 4b-1, but with no significant difference compared to the control group. As the time prolonged, the relative cell viability of each concentration group showed a decreasing trend, which showed a statistical difference compared to the control group (P < 0.05) when it was treated for 3 h compared to the 1.5 h group (P < 0.01). When treated for 4 h with the peptide 4b-1, there was a statistically significant difference in cell viability compared to the Control group (P < 0.01) as well as a statistically significant difference compared to the 1.5 h group (P < 0.01). However, there was no statistically significant difference in the cell viability between the 3 h group and the 4 h group. Peptide 4b-1 exhibited the highest cell viability at the concentration of 10 µg/mL. Therefore, the peptide concentration of 10 µg/mL and treatment time of 1.5 h on CIA mouse spleen cells were selected as the activity measurement conditions for subsequent experiments.
CII(263–272), AP7, 4a, 4b-1, 4b-3 and 4b-4 were selected for stimulation of the CIA mouse spleen cells in vitro. The secretion of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by using the Elisa method (Fig. 2). We found that the secretion of IL-6 stimulated by N-glycopeptides 4b-1 and 4b-3 was significantly reduced compared to O-glycopeptide 4a (P < 0.01 and P < 0.05). Similarly, the secretion of TNF-α stimulated by N-glycopeptides 4b-1 and 4b-3 was significantly reduced compared to O-glycopeptide 4a (P < 0.01 and P < 0.05). These results indicated that IL-6 and TNF-α secretion could be down-regulated by the synthesized N-glycopeptides. Vaccination of mice with CII glycopeptide fragment 4a alone or in complex with the class Ⅱ MHC Aq protein [8] has been shown to prevent development of collagen-induced arthritis, a mouse model for RA. This glycopeptide 4a, which is a fragment from type Ⅱ collagen, was also recognized by T-cells isolated from a cohort of RA patients [27]. In the activation of TCR, the secretion of IL-2, IL-6 and TNF-α stimulated by glycopeptides might be considered as significant markers. The moderate increased secretion of inflammatory factors was needed for the immunogenicity. The results in Fig. 2 indicated that our peptides 4b-1 and 4b-3 had moderate immunogenic effects and could be developed as therapeutic RA vaccines. Further research will be performed to verify the effect of our N-glycopeptides as RA vaccines in the future.
In conclusion, the structure of CII(263–272) was modified to explore the effect of N-linked CII glycopeptides on the secretion of pro-inflammatory factors by CIA mouse spleen cells. 30 peptides were synthesized in the yields of 3%–35%. Two N-glycosylated CII peptides were identified to have stronger binding ability to DR4 protein and weaker proinflammatory effect than O-glycosylated native CII peptide fragment through SPR assay and spleen cell stimulation experiment. The studied glycopeptides could be developed as therapeutic RA vaccines.
Declaration of competing interest
Less
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
Less
This project was supported by the National Natural Science Foundation of China (Nos. 81930097, 21977005, 82151223), and supported by the National Key R & D Program of China (No. 2022YFF1203005).
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2023.108762.
References
Less
[1]
J.K. Pedersen, N.K. Kjær, A.J. Svendsen, K. Hørslev-Petersen, Rheumatol. Int. 29 (2009) 411–415.
[2]
Y.T. Wen, M. Zhang, Y.X. Yao, et al., Chin. Chem. Lett. 34 (2023) 107549.
[3]
D.E. Trentham, A.S. Townes, A.H. Kang, J. Exp. Med. 146 (1977) 857–868.
[4]
A. VanderBorght, P. Geusens, J. Raus, P. Stinissen, Semin. Arthritis. Rheum. 1 (2001) 160–175.
[5]
M. Cornelia, M.D. Weyand, C. Kevin, et al., Ann. Intern. Med. 117 (1992) 801–806.
[6]
E.F. Rosloniec, K.B. Whittington, D.D. Brand, L.K. Myers, J.M. Stuart, Cell. Immunol. 172 (1996) 21–28.
[7]
E. Michaёlsson, J. Broddefalk, A. Engstrom, J. Kihlberg, R. Holmdahl, Eur. J. Immunol. 26 (1996) 1906–1910.
[8]
B. Dzhambazov, K. Nandakumar, J. Kihlberg, et al., J. Immunol. 176 (2006) 1525–1533.
[9]
R.G. Spiro, J. Biol. Chem. 242 (1967) 4813–4823.
[10]
R. Li, X. Li, Z.G. Li, Clin. Immunol. 118 (2006) 317–323.
[11]
Y.J. Cheng, Q. Zhou, Z.G. Li, Scand. J. Immunol. 61 (2005) 260–265.
[12]
C. Lindgren, M. Tyagi, J. Viljanen, et al., J. Med. Chem. 61 (2018) 4774–4790.
[13]
E. Wakamatsu, I. Matsumoto, Y. Yoshiga, et al., Mod. Rheumatol. 19 (2009) 366–371.
[14]
B. Holm, J. Bäcklund, M.A.F. Recio, R. Holmdahl, J. Kihlberg, ChemBioChem 3 (2002) 1209–1222.
[15]
B. Holm, S.M. Baquer, L. Holm, R. Holmdahl, J. Kihlberg, Bioorg. Med. Chem. 11 (2003) 3981–3987.
[16]
E. Michaёlsson, M. Andersson, A. Engström, R. Holmdahl, Eur. J. Immunol. 22 (1992) 1819–1825.
[17]
R.M. Williams, M.N. Im, J. Am. Chem. Soc. 113 (1991) 9276–9286.
[18]
U. Schöllkopf, U. Groth, C. Deng, Angew. Chem. 93 (1981) 793–795.
[19]
L. Guo, T.B. Liu, K. Chen, et al., Org. Biomol. Chem. 12 (2014) 7310–7317.
[20]
U.M. Abdel-Motal, L. Berg, A. Rosén, et al., Eur. J. Immunol. 26 (1996) 544–551.
[21]
E.F. Rosloniec, K.B. Whittington, D.D. Brand, L.K. Myers, J.M. Stuart, Cell. Immunol. 172 (1996) 21–28.
[22]
M. Johannes, M.A. Brimble, J. Org. Chem. 78 (2013) 12809–12813.
[23]
E. Durantie, C. Bucher, R. Gilmour, Chem. Eur. J. 18 (2012) 8208–8215.
[24]
J. Wang, W.J. Qi, G.S. Chen, Chin. Chem. Lett. 30 (2019) 587–591.
[25]
J. Marin, M.A. Blaton, J.P. Briand, et al., ChemBioChem 6 (2005) 1796–1804.
[26]
J. Ameijde, H.B. Albada, R.M.J. Liskamp, J. Chem. Soc. Perkin Trans. 1 (2002) 1042–1049.
[27]
J. Bäcklund, S. Carlsen, T. Höger, et al., Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9960–9965.
Appendix
Less
Year 2024 volume 35 Issue 5
PDF
44
24
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2023.108762
  • Receive Date：2023-05-11
  • Online Date：2025-11-21
  • Published：2024-05-15
Article Data
Affiliations
History
  • Received：2023-05-11
  • Revised：2023-06-29
  • Accepted：2023-07-02
Affiliations
    a State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
    b Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2023.108762
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House